Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03357731 · ClinicalTrials.gov registry record · Phase 2

A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function

A Phase 2 study of Heart Failure and Cardiac Failure, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 2
Development phase
49
Enrollment target
18
Study locations

NCT03357731 is a Phase 2 study of Heart Failure and Cardiac Failure that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 49 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (98% lower). The trial reports 18 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03357731, a Phase 2 study of Heart Failure and Cardiac Failure, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 2
Development phase
49 participants
Enrollment target
18
Study locations

Study Summary

The purpose of this study is to evaluate the effects of BMS-986231 on systolic and diastolic parameters in patients with heart failure and low ejection fraction.

Conditions Studied

Heart Failure Cardiac Failure Reduced Ventricular Ejection Fraction

Interventions

  • OTHER Placebo
  • DRUG HNO Donor
  • DRUG Nitroglycerin (NTG)

Study Locations (18)

Other

  • Local Institution - Groiningen
  • Local Institution - Edinburgh
  • Local Institution - Glasgow
  • Local Institution - Glasgow
  • Local Institution - Glasgow
  • Local Institution - Harrow
  • Local Institution - London
  • Local Institution - London
  • Local Institution - London

California

  • Orange County Research Center - Tustin

Illinois

  • Northwestern Medicine - Chicago

Indiana

  • Indiana University School of Medicine-Indianapolis - Indianapolis

Massachusetts

  • Brigham and Womens Hospital - Boston

North Carolina

  • Duke Advanced Heart and Lung Failure Clinic - Durham

Virginia

  • Inova Heart and Vascular Institute - Falls Church

Aichi-ken

  • Local Institution - Nagoya

Trial Details

FieldValue
Enrollment Target 49 participants
Start Date 2017-11-30
Est. Completion 2019-05-10
Phase Phase 2

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03357731

The ClinicalTrials.gov registry entry for NCT03357731 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (98% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Heart Failure appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT03357731 reports 18 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT03357731 about?

NCT03357731 is a clinical study titled "A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function". The purpose of this study is to evaluate the effects of BMS-986231 on systolic and diastolic parameters in patients with heart failure and low ejection fraction.

What is the current status of trial NCT03357731?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2017-11-30. Estimated completion is 2019-05-10.

What conditions does trial NCT03357731 study?

This clinical trial studies the following conditions: Heart Failure, Cardiac Failure, Reduced Ventricular Ejection Fraction.

What interventions are being tested in trial NCT03357731?

The interventions under investigation include: Placebo (OTHER), HNO Donor (DRUG), Nitroglycerin (NTG) (DRUG).

Who is sponsoring clinical trial NCT03357731?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03357731 being conducted?

This trial has 18 study locations across California, Illinois, Indiana, Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure

All registered trials for this condition

Cardiac Failure

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.